ARS Pharma rises after Canada clears needle-free allergy spray

ARS Pharmaceuticals

15/04/2026 11:16

** Shares of ARS Pharmaceuticals SPRY.O rise 2% to $8.30 premarket

** Drug developer says Health Canada approved neffy, a needle-free epinephrine nasal spray for severe allergic reactions in adults and children weighing over 30 kg

** Co says the spray is used at the first signs of an allergic reaction, a life-threatening condition where the body overreacts to foods, insect stings or medicines

** Says neffy offers an alternative to traditional epinephrine auto-injectors, which some patients avoid due to fear of needles

** Adds says neffy has a 30-month shelf life and can withstand high temperatures and accidental freezing

** Says ALK-Abelló will market neffy in Canada, with availability expected by summer 2026

** Says it plans to seek approval later this year for a lower-dose version for younger children

** As of last close, stock down ~30% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))